id: extended_release_trazodone_treatment_to_anxiety_symptoms_mdd_aud
name: Extended-Release Trazodone Treatment â†’ Anxiety Symptoms in MDD+AUD
from_node:
  node_id: extended_release_trazodone_treatment
  node_name: Extended-Release Trazodone Treatment
to_node:
  node_id: anxiety_symptoms_mdd_aud
  node_name: Anxiety Symptoms in MDD+AUD
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Extended-release trazodone (150-300 mg/day) is administered to patients
  with comorbid MDD and AUD'
- 'Step 2: Trazodone has anxiolytic properties through its effects on serotonin receptors
  and alpha-adrenergic antagonism'
- 'Step 3: Over the treatment period, anxiety symptoms are significantly reduced alongside
  improvements in depression and sleep'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Marco Di Nicola et al. 2023. "Update on Pharmacological Treatment
    for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-release
    Trazodone.." *Current neuropharmacology*. https://doi.org/10.2174/1570159X21666230403080624'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:07.056638'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/extended_release_trazodone_treatment_to_anxiety_symptoms_mdd_aud.yaml
_category: healthcare_access
